The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials

2017 ◽  
Vol 233 (1) ◽  
pp. 378-386 ◽  
Author(s):  
Maryam Moradi Binabaj ◽  
Afsane Bahrami ◽  
Soodabeh ShahidSales ◽  
Marjan Joodi ◽  
Mona Joudi Mashhad ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Promoter Methylation ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

Clinical Significance of O-6-Methylguanine-DNA-Methyltransferase Promoter Methylation in Patients with Esophageal Carcinoma: A Systematic Meta-Analysis

2017 ◽  
Vol 36 (2) ◽  
pp. 89-97 ◽  
Author(s):  
Yan Zhang ◽  
Ti Tong
Keyword(s):  
Esophageal Carcinoma ◽  
Promoter Methylation ◽  
Dna Methyltransferase ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Mgmt Promoter Methylation ◽  
Lymph Node Status ◽  
Tissue Samples ◽  
Methylguanine Dna Methyltransferase ◽  
Mgmt Promoter

Background: The correlation between O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and esophageal cancer remains controversial. This study was conducted to evaluate the clinical effect of MGMT promoter methylation on esophageal carcinoma patients. Methods: A literature search was conducted in the PubMed, EMBASE, EBSCO, and Cochrane Library databases. The overall OR and corresponding 95% CI were calculated using the random-effects model. Results: Finally, 17 eligible studies were identified in this meta-analysis; these studies included a total of 1,368 patients with esophageal carcinoma and 1,489 with nonmalignant controls. MGMT promoter methylation was significantly higher in esophageal carcinoma tissue samples than in nonmalignant tissue samples (OR 3.64, p < 0.001). Promoter methylation of the MGMT gene was not associated with gender, cigarette smoking, drinking behavior, or tumor differentiation, but MGMT promoter methylation was correlated with age (≥60 vs. <60 years: OR 1.64, p = 0.028), lymph node status (positive status vs. negative status: OR 2.39, p = 0.024), and clinical stage (stages 3-4 vs. 1-2: OR 10.59, p < 0.001). Conclusions: Our findings suggest that MGMT promoter methylation may be correlated with esophageal cancer carcinogenesis and could be associated with age, lymph node status, and clinical stage.

The Association Between MGMT Promoter Methylation and Patients with Gastric Cancer: A Meta-Analysis

2017 ◽  
Vol 21 (4) ◽  
pp. 213-221 ◽  
Author(s):  
Xiaolong Yuan ◽  
Jifei Xu ◽  
Weiyang Fang ◽  
Zhenfeng Zhao ◽  
Fan Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter

scholarly journals Immunotherapeutic early-phase clinical trials and malignant gliomas: a single-center experience and comprehensive immunophenotyping of circulating leukocytes

2021 ◽  
Author(s):  
Matteo Simonelli ◽  
Pasquale Persico ◽  
Arianna Capucetti ◽  
Claudia Carenza ◽  
Sara Franzese ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Promoter Methylation ◽  
Early Phase ◽  
Univariate Analysis ◽  
Malignant Gliomas ◽  
Mgmt Promoter Methylation ◽  
Control Group ◽  
Large Expansion ◽  
Mgmt Promoter ◽  
Early Phase Clinical Trials

Abstract Background Immunotherapeutic early-phase clinical trials (ieCTs) increasingly adopt large expansion cohorts exploring novel agents across different tumor types. High-grade glioma (HGG) patients are usually excluded from these trials. Methods Data of patients with recurrent HGGs treated within multicohort ieCTs between February 2014 and August 2019 (experimental group, EG) at our Phase I Unit were retrospectively reviewed and compared to a matched control group (CG) of patients treated with standard therapies. We retrospectively evaluated clinical, laboratory, and molecular parameters through univariate and multivariate analysis. A prospective characterization of circulating leukocyte subpopulations was performed in the latest twenty patients enrolled in the EG, with a statistical significance cutoff of p &lt;0.1. Results Thirty HGG patients were treated into six ieCTs. Fifteen patients received monotherapies (anti PD-1, anti CSF-1R, anti TGFβ, anti cereblon), fifteen patients combination regimens (anti PD-L1 + anti CD38, anti PD-1 + anti CSF-1R). In the EG, median progression-free survival and overall survival (OS) from treatment initiation were 1.8 and 8.6 months; twelve patients survived more than 12 months, and two of them more than six years. Univariate analysis identified O 6-methylguanine DNA methyltransferase (MGMT) promoter methylation and total protein value at six weeks as significantly correlated with a better outcome. Decreased circulating neutrophils and increased conventional dendritic cells levels lead to significantly better OS. Conclusions A subgroup of EG patients achieved remarkably durable disease control. MGMT promoter methylation identifies patients who benefit more from immunotherapy. Monitoring dynamic changes of innate immune cell populations may help to predict clinical outcomes.

The Prognosis of MGMT Promoter Methylation in Glioblastoma Patients of Different Race: A Meta-analysis

2014 ◽  
Vol 39 (12) ◽  
pp. 2277-2287 ◽  
Author(s):  
Haiyu Yang ◽  
Danping Wei ◽  
Kunxian Yang ◽  
Wenru Tang ◽  
Ying Luo ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Meta Analysis ◽  
Mgmt Promoter Methylation ◽  
Mgmt Promoter
Sign in / Sign up

Export Citation Format

Share Document